Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 26, Issue 2, 2011, Pages 150-157

  Waldemar, Gunhild ^a   Gauthier, Serge ^b   Jones, Roy ^c   Wilkinson, David ^d   Cummings, Jeffrey ^e   Lopez, Oscar ^f   Zhang, Richard ^g   Xu, Yikang ^g   Sun, Yijun ^h   Knox, Sean ⁱ   Richardson, Sharon ^h   MacKell, Joan ^g  

^a Rigshospitalet   (Denmark)

^b MCGILL UNIVERSITY   (Canada)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

^d MOORGREEN HOSPITAL   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g PFIZER INC   (United States)

^h EISAI INC   (United States)

ⁱ EISAI CO LTD   (Japan)

Author keywords

Alzheimer's disease; apathy; donepezil; Neuropsychiatric Inventory

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; APATHY; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APATHY; BRIEF PSYCHIATRIC RATING SCALE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 78651464885     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2507     Document Type: Article

References (33)

1. Aalten P, Verhey FR, Boziki M, et al. 2007. Neuropsychiatric syndromes in dementia. Results: from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord 24 (6): 457 - 463.
2. American Psychiatric Association. 1995. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition DSM- IV. American Psychiatric Association Publishing: Arlington, VA.
3. Apostolova LG, Akopyan GG, Partiali N, et al. 2007. Structural correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 24 (2): 91 - 97.
4. Benoit M, Robert PH, Staccini P, et al. 2005. One- year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study. J Nutr Health Aging 9 (2): 95 - 99.
5. Cummings JL, McRae T, Zhang R,. 2006a. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 14 (7): 605 - 612.
6. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (12): 2308 - 2314.
7. Cummings JL, Schneider E, Tariot PN, Graham SM,. 2006b. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67 (1): 57 - 63.
8. Drijgers RL, Aalten P, Winogrodzka A, Verhey FRJ, Leentjens AFG,. 2009. Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review. Dement Geriatr Cogn Disord 28 (1): 13 - 22.
9. Feldman H, Cummings J, Schwam E,. 2008. Evaluating neuropsychiatric symptoms in Alzheimer's disease: a novel approach using bubble plots to evaluate donepezil treatment effects [abstract]. Alzheimers Dement 4 (4Suppl): T763 - T764.
10. Feldman H, Gauthier S, Hecker J, et al. 2001. A 24- week, randomized, double- blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (4): 613 - 620.
11. Feldman H, Gauthier S, Hecker J, et al. 2003. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 51 (6): 737 - 744.
12. Gauthier S, Loft H, Cummings J,. 2008. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 23 (5): 537 - 545.
13. Herrmann N, Rabheru K, Wang J, Binder C,. 2005. Galantamine treatment of problematic behavior in Alzheimer disease: post- hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 13 (6): 527 - 534.
14. Herrmann N, Rothenburg LS, Black SE, et al. 2008. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 28 (3): 296 - 301.
15. Kaufer D, Catt K, Pollock B, et al. 1998a. Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology 50: A89.
16. Kaufer DI, Cummings JL, Christine D, et al. 1998b. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 46 (2): 210 - 215.
17. Lopez OL, Zivkovic S, Smith G, et al. 2001. Psychiatric symptoms associated with cortical- subcortical dysfunction in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 13 (1): 56 - 60.
18. Lovheim H, Sandman PO, Karlsson S, Gustafson Y,. 2008. Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. Int Psychogeriatr 20 (4): 777 - 789.
19. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL,. 2006. Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 21 (3): 144 - 147.
20. Marshall GA, Monserratt L, Harwood D, et al. 2007. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 64 (7): 1015 - 1020.
21. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939 - 944.
22. Migneco O, Benoit M, Koulibaly PM, et al. 2001. Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients. Neuroimage 13 (5): 896 - 902.
23. Onyike CU, Sheppard JM, Tschanz JT, et al. 2007. Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry 15 (5): 365 - 375.
24. Petry S, Cummings JL, Hill MA, Shapira J,. 1989. Personality alterations in dementia of the Alzheimer type: a three- year follow- up study. J Geriatr Psychiatry Neurol 2 (4): 203 - 207.
25. Piccininni M, Di Carlo A, Baldereschi M, Zaccara G, Inzitari D,. 2005. Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord 19 (5-6): 276 - 281.
26. Robert PH, Clairet S, Benoit M, et al. 2002. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 17 (12): 1099 - 1105.
27. Robert P, Onyike CU, Leentjens AF, et al. 2009. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 24 (2): 98 - 104.
28. Sockeel P, Dujardin K, Devos D, et al. 2006. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (5): 579 - 584.
29. Starkstein SE, Petracca G, Chemerinski E, Kremer J,. 2001. Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 158 (6): 872 - 877.
30. Tariot PN, Cummings JL, Katz IR, et al. 2001. A randomized, double- blind, placebo- controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49: 1590 - 1599.
31. Tune L, Tiseo PJ, Ieni J, et al. 2003. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24- week, double- blind, placebo- controlled study. Am J Geriatr Psychiatry 11 (2): 169 - 177.
32. van Reekum R, Stuss DT, Ostrander L,. 2005. Apathy: why care? J Neuropsychiatry Clin Neurosci 17 (1): 7 - 19.
33. Winblad B, Engedal K, Soininen H, et al. 2001. A 1- year, randomized, placebo- controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (3): 489 - 495.